WO2005097171A1 - 抗肥満薬 - Google Patents
抗肥満薬 Download PDFInfo
- Publication number
- WO2005097171A1 WO2005097171A1 PCT/JP2005/006024 JP2005006024W WO2005097171A1 WO 2005097171 A1 WO2005097171 A1 WO 2005097171A1 JP 2005006024 W JP2005006024 W JP 2005006024W WO 2005097171 A1 WO2005097171 A1 WO 2005097171A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agf
- mice
- mouse
- seq
- amino acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title abstract description 26
- 230000003579 anti-obesity Effects 0.000 title abstract description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 42
- 208000008589 Obesity Diseases 0.000 claims abstract description 40
- 235000020824 obesity Nutrition 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 36
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 25
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 25
- 239000002157 polynucleotide Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 235000013402 health food Nutrition 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 71
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 30
- 230000004584 weight gain Effects 0.000 claims description 27
- 235000019786 weight gain Nutrition 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 239000000883 anti-obesity agent Substances 0.000 claims description 10
- 229940125710 antiobesity agent Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 101710085819 Angiopoietin-related protein 6 Proteins 0.000 abstract description 158
- 102100034599 Angiopoietin-related protein 6 Human genes 0.000 abstract description 153
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 4
- 241000699670 Mus sp. Species 0.000 description 223
- 241000699666 Mus <mouse, genus> Species 0.000 description 120
- 210000004369 blood Anatomy 0.000 description 59
- 239000008280 blood Substances 0.000 description 59
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 52
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 52
- 239000008103 glucose Substances 0.000 description 50
- 241000701161 unidentified adenovirus Species 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 36
- 101100434901 Mus musculus Angptl6 gene Proteins 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 34
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 30
- 101000924549 Homo sapiens Angiopoietin-related protein 6 Proteins 0.000 description 29
- 102000055024 human ANGPTL6 Human genes 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 27
- 102000004877 Insulin Human genes 0.000 description 26
- 108090001061 Insulin Proteins 0.000 description 26
- 229940125396 insulin Drugs 0.000 description 26
- 210000000593 adipose tissue white Anatomy 0.000 description 25
- 230000037396 body weight Effects 0.000 description 25
- 235000009200 high fat diet Nutrition 0.000 description 25
- 230000001965 increasing effect Effects 0.000 description 25
- 208000021017 Weight Gain Diseases 0.000 description 23
- 210000001789 adipocyte Anatomy 0.000 description 22
- 210000002027 skeletal muscle Anatomy 0.000 description 22
- 210000000577 adipose tissue Anatomy 0.000 description 17
- 210000003486 adipose tissue brown Anatomy 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 108091008146 restriction endonucleases Proteins 0.000 description 15
- 206010022489 Insulin Resistance Diseases 0.000 description 14
- 230000036284 oxygen consumption Effects 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 210000004392 genitalia Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 235000000891 standard diet Nutrition 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 206010020880 Hypertrophy Diseases 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000001596 intra-abdominal fat Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 6
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 230000004153 glucose metabolism Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000004003 subcutaneous fat Anatomy 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 4
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- -1 liquid paraffin Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 108010091748 peptide A Proteins 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010021033 Hypomenorrhoea Diseases 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- YXQXLHSRJUFMFD-UHFFFAOYSA-N 3-[(3,4-dihydroxyphenyl)methyl]-2h-chromene-7,8-diol Chemical group C1=C(O)C(O)=CC=C1CC1=CC2=CC=C(O)C(O)=C2OC1 YXQXLHSRJUFMFD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 101000622007 Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 241000701151 Human adenovirus 6 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 1
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000800132 Mus musculus Thyroglobulin Proteins 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 101150027734 cript gene Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to an Angiopoietin-related growth factor
- AGF anti-obesity drug
- AGF a derivative thereof or a polynucleotide encoding the same as an active ingredient.
- the anti-obesity drug of the present invention can be given in various forms that can be administered as a medicament, for example, in the form of a food or drink as a health food (preferably a functional food) or a feed.
- Exercise therapy and diet therapy are basic methods for improving obesity, but it is difficult to continuously perform both.
- sibutramine and orlistat are mainly used worldwide. However, their effectiveness is weak, and both have side effects.
- Japan only mazindol is approved, but its application is limited to highly obese people, and the administration period is also limited (Non-patent Document 2).
- Lebutin is well known as a factor involved in the accumulation of adipose tissue that causes obesity and diabetes.
- Leptin is a weight gain inhibitory hormone, and it is known that deficiency of leptin increases appetite, reduces energy consumption, and leads to obesity.
- Such discovery of factors involved in adipose tissue accumulation and adipocyte hypertrophy is extremely useful for the development of a therapeutic drug for diseases such as obesity, diabetes, or hyperlipidemia (Non-patent Document 6).
- Angiopoietin-related growth factor is a secreted protein having a coiled-coil domain on the N-terminal side and a fibrinogen-like domain on the C-terminal side.
- AGF is the same as NL8 reported in Patent Document 1, and it has been reported that when NL8 is stably expressed in CHO cells and implanted subcutaneously in nude mice, CHO becomes capable of forming tumors.
- AGF was added to angiogenic activity, epidermal cell proliferating activity, chondrocyte proliferating activity, and wound healing promoting activity using transgenic mice, etc., in which AGF was forcibly expressed in epidermal cells using the K14 promoter. And have tissue regeneration activity (Patent Document 1, Non-Patent Document 7). However, we did not find any knowledge about other physiological functions of AGF.
- Non-patent document 1 “Metabolism”, (USA), 1987, 36 volumes, p.54_ 59
- Non-patent document 2 Japanese clinical practice", 2003, 61 volumes, extra number 6, obesity Disease, p.649—654
- Non-patent document 3 "Japanese clinical practice", 2002, Vol. 60, extra number 9, New Diabetes 3, p.31 0-331
- Non-Patent Document 4 "The History of Medicine", 2000, vol. 192, p.513-518
- Non-Patent Document 5 “Ayumi of Medicine”, 2000, vol. 192, p.541-545
- Non-Patent Document 6 "Trends in Molecular Medicine"
- Non-Patent Document 7 “Proceedings of the national academy of sciences of the United States of America” J, (Proceedings of the national academy of sciences of the United States of America) United States), 2003, vol. 100, p. 9494-9499
- Patent document 1 International publication W099 / 15653 pamphlet
- Patent document 2 International publication WO03 / 083114 pamphlet
- An object of the present invention is to provide a novel anti-obesity drug.
- AGF knock-out mice and AGF transgenic (Tg) mice have been produced and analyzed to show that AGF has anti-obesity, anti-diabetic, and anti-hyperlipidemic effects. Clarified to have. That is, it was found that AGF knockout mice showed remarkable fattening (Example 3). Furthermore, AGF knockout mice have increased fat tissue weight associated with obesity (Example 4), enlarged fat cells (Example 5), and skeletal muscle, which is known to increase in obesity. In addition, it was found that the amount of triglyceride in liver tissue increased (Example 6).
- mice to which the AGF-expressing adenovirus was administered weight gain was suppressed and glucose tolerance was improved (Examples 15 and 20), and another AGF transgenic mouse (K14-AGF Tg mouse; (Mice expressing AGF in the epidermis forcibly) have an antiobesity effect, an adipose tissue reducing effect, and an insulin sensitivity enhancing effect (Examples 18 and 19).
- AGF is an effective component of a therapeutic agent for anti-obesity, diabetes, and / or hyperlipidemia, and completed the present invention.
- An antiobesity agent a therapeutic agent for diabetes, and / or hyperlipidemia, comprising a polypeptide selected from the group consisting of the following (a) to (d) or a polynucleotide encoding the polypeptide as an active ingredient:
- Therapeutic agent :
- a method for treating or preventing obesity, diabetes, and / or hyperlipidemia comprising administering an effective amount to a subject in need of treatment or prevention of Z or hyperlipidemia, and
- polypeptide or a polynucleotide encoding the same for producing an antiobesity agent, a therapeutic agent for diabetes, and a therapeutic agent for Z or hyperlipidemia.
- transgenic animal refers to an animal in which a promoter and a gene have been introduced into a chromosome, and the gene has been forcibly expressed at a desired location. It is used to mean an animal in which the expression of a specific gene has been deleted by genetic manipulation.
- AGF is useful as an active ingredient of an antiobesity agent, a therapeutic agent for diabetes, and / or a therapeutic agent for hyperlipidemia.
- FIG. 1 is a drawing schematically showing the structure of plasmid pBS-loxP-lox71-mAGF-iS geo.
- the symbols “pro.” And “pri.” Mean the promoter and primer, respectively.
- FIG. 2 is a graph showing changes in body weight of AGF K ⁇ mice.
- the horizontal axis indicates the age (week), and the vertical axis indicates the body weight (g).
- the symbols “WT”, “HTR”, and “HM” mean WT mouse, heterozygous KO mouse, and homozygous KO mouse, respectively.
- FIG. 3 is a graph showing the change in genital fat (white adipose tissue) weight of CAG-AGF Tg mice (standard diet).
- the vertical axis indicates white adipose tissue weight (g) / body weight (g). Also, the symbol "W
- T and Tg mean WT and Tg mice, respectively.
- FIG. 4 is a graph showing changes in the weight of genital fat (white adipose tissue) in CAG—AGF Tg mice (high fat diet load).
- the vertical axis indicates white adipose tissue weight (g) / body weight (g).
- the symbols “WT” and “Tg” mean WT mouse and Tg mouse, respectively.
- FIG. The vertical axis indicates white adipose tissue weight (g). Also, the symbols “WT”, ⁇ TRJ and “HM” mean WT mouse, AGF heterozygous K ⁇ mouse, and AGF homozygous K ⁇ mouse, respectively.
- Garden 6 is a graph showing changes in genital fat (white adipose tissue) weight (white adipose tissue weight ⁇ body weight) of AGF K ⁇ mice.
- the vertical axis indicates white adipose tissue weight (g) / body weight (g).
- the symbols “WT”, “HTR”, and “HM” mean WT mice, AGF heterozygous KO mice, and AGF homozygous K ⁇ mice, respectively.
- FIG. 7 is a drawing showing the morphology of adipocytes in CAG_AGF Tg mice. The symbol "TG
- FIG. 10 is a graph showing the TG content in the tissue (liver) of CAG—AGF Tg mice.
- the horizontal axis shows the high fat diet load (for months), and the vertical axis shows the TG content (mg / g tissue).
- the symbols “WT” and “Tg” mean WT mouse and Tg mouse, respectively.
- FIG. 11 is a graph showing the TG content in the tissue (skeletal muscle) of CAG—AGF Tg mice.
- the horizontal axis shows the high fat diet load (for months), and the vertical axis shows the TG content (mg / g tissue). Also, the symbol "W
- T and Tg mean WT and Tg mice, respectively.
- FIG. 12 is a graph showing the TG content in tissues of AGF KO mice. The vertical axis shows the TG content (mg
- the symbols “L” and “SM” on the horizontal axis represent liver and skeletal muscle, respectively, and the symbols “WT”, “HTR” and “HM” represent WT mouse and heterozygous mouse, respectively. , And homozygous mice.
- FIG. 13 is a graph showing the results of a glucose tolerance test (blood glucose level) of AGF K ⁇ mice.
- the horizontal axis indicates time (minutes), and the vertical axis indicates blood glucose level (mgZdL).
- the symbols "WT” and “HM” mean WT mouse and homozygous mouse, respectively.
- FIG. 14 is a graph showing the results of a glucose tolerance test (plasma insulin) in AGF K ⁇ mice.
- the horizontal axis represents time (minutes), and the vertical axis represents plasma insulin (ngZmL).
- WT and HM mean a WT mouse and a homo KO mouse, respectively.
- FIG. 15 is a graph showing oxygen consumption of CAG_AGF Tg mice.
- lane 1 is “light period”
- lane 2 is “period”
- lane 3 is “24 hours”
- the vertical axis is VO (mL / mL). kg / min).
- WT and Tg mean WT mouse and Tg mouse, respectively.
- Mouse is a graph showing the results of a glucose metabolism test in mice administered with AGF-expressing adenovirus. Closed circles are the results of mice administered with mAGF-Adeno, and open circles are the results of mice administered with Cont-Adeno. The horizontal axis is the elapsed time (minutes), and the vertical axis is the blood glucose level (mgZd L).
- FIG. 17 is a graph showing plasma insulin levels (vertical axis; ng / mL) of CAG-AGF Tg mice and Ritamate WT mice bred on a high fat diet.
- the symbols "TG” and "NTG” are a graph showing plasma insulin levels (vertical axis; ng / mL) of CAG-AGF Tg mice and Ritamate WT mice bred on a high fat diet. The symbols "TG” and "NTG"
- FIG. 19 is a graph showing serum free fatty acid concentrations (vertical axis; ⁇ Eq / L) of CAG-AGF Tg mice and Ritamate WT mice bred on a high fat diet.
- the symbols "TG” and "NTG” are a graph showing serum free fatty acid concentrations (vertical axis; ⁇ Eq / L) of CAG-AGF Tg mice and Ritamate WT mice bred on a high fat diet.
- FIG. 20 is a graph showing the results of a glucose metabolism test of CAG—AGF Tg mice and Rita-Mate WT mice.
- the symbols "TG” and “NTG” mean CAG-AGF Tg mouse and Ritamate WT mouse, respectively.
- the horizontal axis is elapsed time (minutes), and the vertical axis is blood glucose level (mg / dL).
- FIG. 21 is a graph showing the results of an insulin sensitivity test of CAG_AGF Tg mice and Rita-mate WT mice.
- the symbols "TG” and “NTG” mean CAG-AGF Tg mouse and Ritamate WT mouse, respectively.
- the horizontal axis is the elapsed time (minutes), and the vertical axis is the ratio (%) of the blood glucose level after administration to the blood glucose level before insulin administration.
- FIG. 22 is a graph showing visceral adipose tissue weights in K14_AGF Tg mice and Rita-Mate WT mice.
- the symbols "K14_AGF” and “NTG” mean K14-AGF Tg mouse and Ritamate WT mouse, respectively.
- the vertical axis represents the percentage (%) of visceral fat tissue weight per body weight.
- FIG. 23 Subcutaneous adipose tissue weight in K14-AGF Tg mice and Ritamate WT mice
- K14_AGF and NG mean K14-AGF Tg mouse and Ritamate WT mouse, respectively.
- the vertical axis represents the percentage (%) of subcutaneous adipose tissue weight per body weight.
- FIG. 24 is a graph showing the results of an insulin sensitivity test on K14_AGF Tg mice and Rita-mate WT mice.
- the symbols "K14_AGF” and “NTG” mean K14-AGF Tg mouse and Ritamate WT mouse, respectively.
- the horizontal axis indicates elapsed time (minutes), and the vertical axis indicates the ratio (%) of the blood glucose level after administration to the blood glucose level before insulin administration.
- FIG. 25 is a graph showing the results of a glucose metabolism test in mice administered with human AGF-expressing adenovirus. Closed circles are the results for hAGF-Adeno-administered mice, and open circles are for Cont-Adeno-administered mice. The horizontal axis indicates elapsed time (minutes), and the vertical axis indicates blood glucose level (mg / dL).
- the antiobesity agent, antidiabetic agent, and Z or hyperlipidemia agent of the present invention are selected from the group consisting of the following (a) to (d):
- the polypeptide, or at least one of the polynucleotides encoding said polypeptide, can be included as an active ingredient:
- the "anti-obesity drug” in the present specification includes both drugs used for treating obese patients and drugs used prophylactically for obese subjects.
- the term “diabetic drug” in this specification includes both drugs used for treating patients with diabetes and drugs used prophylactically for subjects prone to diabetes.
- the term "agent for treating hyperlipidemia” herein includes a drug used for treating a patient having hyperlipidemia and a drug used prophylactically for a subject having a tendency to hyperlipidemia. And both are included.
- the polypeptide as an active ingredient of the medicament of the present invention includes human AGF comprising a sequence consisting of amino acids 1 to 450 in the amino acid sequence represented by SEQ ID NO: 3, or a polypeptide represented by SEQ ID NO: 5.
- Mouse AGF consisting of a sequence consisting of amino acids 1 to 433 in the amino acid sequence shown is preferred.
- the amino acid sequence represented by SEQ ID NO: 3 is the amino acid sequence of human AGF precursor.
- Human AGF has a signal sequence (120-1) at the N-terminus, and the signal sequence is cleaved when secreted and expressed outside the cell. It has a human mature AGF force physiological activity consisting of a sequence consisting of amino acids 1 to 450 in the amino acid sequence represented by SEQ ID NO: 3 in which the signal sequence is cleaved.
- the amino acid sequence represented by SEQ ID NO: 5 is the amino acid sequence of mouse AGF precursor.
- Mouse AGF has a signal sequence (-24 to -1) at the N-terminus, and the signal sequence is cleaved when secreted and expressed outside the cell.
- Mature mouse AGF consisting of a sequence consisting of amino acids 1 to 433 in the amino acid sequence represented by SEQ ID NO: 5 from which the signal sequence has been cleaved has biological activity.
- the polypeptide (b) that can be used as an active ingredient of the medicament of the present invention that is, a sequence consisting of amino acids 1 to 450 in the amino acid sequence represented by SEQ ID NO: 3, Alternatively, in the sequence consisting of amino acids 1 to 433 in the amino acid sequence represented by SEQ ID NO: 5, 1 to 10 (for example, 1 to several) amino acid residues are substituted, deleted, and Z or ⁇
- the polypeptide having the inserted amino acid sequence and having the activity of suppressing weight gain preferably, in each of the above sequences, 1 to 7, more preferably 1 to 5 amino acid residues are substituted, deleted, and And / or a polypeptide containing the inserted amino acid sequence and having an activity of suppressing weight gain.
- the amino acid to be substituted is preferably an amino acid having properties similar to the amino acid before substitution.
- amino acids belonging to each group as shown below are amino acids having properties similar to each other within the group. Substitution of these amino acids for other amino acids in gnorape often does not impair the essential function of the protein. Such amino acid substitution is called a conservative substitution and is known as a technique for converting an amino acid sequence while maintaining the function of a polypeptide.
- Non-polar amino acids Ala, Val, Leu, Ile, Pro, Met, Phe, and TYp
- Uncharged amino acids Gly, Ser, Thr, Cys, Tyr, Asn, and Gin
- Acidic amino acids Asp and Glu
- the method for determining whether or not a certain polypeptide has a weight-gain-inhibiting activity is not particularly limited, and can be confirmed, for example, by the method described in Example 3. That is, a transgenic animal produced using the gene encoding the polypeptide can be bred on a standard diet or a high-fat diet, and the change in body weight can be confirmed by comparing with a wild-type animal. In addition, it can be confirmed by the method described in Example 15 or Example 20. That is, it can be confirmed by administering an adenovirus expressing the polypeptide to a mouse bred on a standard diet or a high fat diet, and comparing the change in body weight with that of a control adenovirus.
- the “stringent conditions” in the polypeptide (c) that can be used as an active ingredient of the medicament of the present invention include “5xSS PE, 5xDenhard's” as conditions for hybridization. ) Solution, 0.5% sodium dodecyl sulfate (SDS), 40% formamide, 200 ⁇ g / mL salmon sperm DNA, 37 ° C overnight. The stricter conditions were about 5xSSPE, 5xdenopate night, 0.5% SDS, 50% honolemamide, 200 ⁇ g ZmL salmon sperm DNA, overnight at 42 ° C.
- loose conditions for washing are ⁇ 5xSSC, 1% SDS, 42 ° C '', and normal conditions are about ⁇ 0.5xSSC, 0.1% SDS, 42 ° C ''. , and the more severe conditions as ⁇ or a "0. 2xSSC, 0. 1 0/0 SDS, 65 ° C " about the conditions.
- the 5XSSPE is composed of 50 mmol ZL sodium phosphate (pH 7.4), 0.75 mol / L NaCl, and 5 mmol / LE DTA.
- the composition of 5XSSC is 0.75 mol / L NaCl and 75 mmol / L. It is sodium taenoate ( ⁇ 70).
- the identity of the polypeptide (d) that can be used as an active ingredient of the medicament of the present invention preferably shows an identity of at least 95% or more and a power of 97% or more.
- the amino acid sequence identity can be determined using the BLAST search algorithm. Specifically, the bl2seq program of the BLAST package (sg 2bit version, version 2.0.12; obtained from NCBI) [Tatiana A. Tatusova,
- polypeptide that can be used as an active ingredient of the medicament of the present invention those containing a signal sequence on the N-terminal side of the polypeptides (a) to (d) are preferable.
- the signal sequence is not limited as long as it is a sequence leading the polypeptide through the membrane.
- the signal sequence described in Biochemistry, 28 (3), 923-930, 1989 can be used.
- the signal sequence IK_20 to 11) in the amino acid sequence represented by SEQ ID NO: 3 or the amino acid represented by SEQ ID NO: 5 A sequence containing the signal system (24 - ⁇ - 1) in the sequence is preferred.
- the amino acid sequence represented by SEQ ID NO: 3 or the amino acid sequence represented by SEQ ID NO: 5 is most preferred.
- the origin of the polypeptide that can be used as an active ingredient of the medicament of the present invention is not limited to humans or mice.
- polypeptides derived from organisms other than human or mouse may also be used as long as they fall under any of the above polypeptides (a) to (d).
- the modified polypeptide can also be used as an active ingredient of the medicament of the present invention.
- polypeptide is preferably a recombinant.
- Polynucleotides encoding the polypeptides (a) to (d), that is, polynucleotides that can be used as an active ingredient of the medicament of the present invention include DNA and RNA, and may be DNA. I like it.
- the polynucleotide for example, a sequence consisting of bases 61 to 1410 in the base sequence represented by SEQ ID NO: 2 or bases 73 to 1371 in the base sequence represented by SEQ ID NO: 4 And a polynucleotide encoding a polypeptide having the activity of inhibiting weight gain.
- At least one of the polypeptides (a) to (d) or a polynucleotide encoding the polypeptide is used for treating or preventing obesity, diabetes, and / or hyperlipidemia.
- Methods for treating or preventing obesity, diabetes, and Z or hyperlipidemia including administering to a subject in need thereof an effective amount.
- the present invention provides a method for producing an anti-obesity agent, a therapeutic agent for diabetes, and a therapeutic agent for Z or hyperlipidemia of the polypeptides (a) to (d) or the polynucleotide encoding the polypeptide. Including the use of
- the method of administering the polypeptide that is the medicament of the present invention includes, for example, oral administration using tablets, pills, capsules, granules, fine granules, powders, or oral solutions, or intravenous injection.
- parenteral administration by injection such as intramuscular injection, suppository, transdermal drug, or transmucosal drug.
- parenteral administration such as transdermal administration or intravenous injection, or the lower part of the gastrointestinal tract that is less affected by digestive enzymes (e.g., jejunum, ileum, colon,
- a preparation containing the polypeptides (a) to (d) as an active ingredient is prepared by using a pharmacologically acceptable carrier, an excipient, and other additives usually used for preparing a polypeptide. It can be prepared as a composition.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injection or physiological saline as a diluent.
- the diluent for the water-insoluble solution or suspension include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80, and the like.
- the composition may further contain wetting agents, emulsifiers, dispersants, stabilizers, solubilizing or solubilizing agents, or preservatives.
- composition is sterilized by, for example, filtration through a bacteria-retaining filter, blending of a bactericide, or irradiation.
- a sterile solid composition can be produced and dissolved in sterile water or another sterile injectable medium before use.
- the medicament of the present invention contains a therapeutically effective amount or a pharmacologically effective amount sufficient to produce the intended effect in the treatment or prevention of obesity, diabetes, and / or hyperlipidemia.
- Confirmation of the effective amount in actual administration can be performed, for example, by measuring the degree of recovery of the target disease.
- the actual amount to be administered depends on various factors, such as the condition, age, and weight of the individual to be treated, and is preferably the amount at which the desired effect is produced without significant side effects. Administered. Those skilled in the art can easily determine such an effective amount, toxicity and the like using a known model animal.
- the amount of the active ingredient is preferably 1 ⁇ g to 2 g per day. More preferably, it is 1 ⁇ g to 200 mg per day.
- a polynucleotide encoding the same may be administered as an antiobesity agent, a therapeutic agent for diabetes, and / or a therapeutic agent for hyperlipidemia in gene therapy.
- dosage forms in gene therapy are classified into two types: non-viral vectors and viral vectors.
- Examples of the method using a non-viral vector include a method using an encapsulated ribosome, a method using an electrostatic ribosome, and a method using HVJ-ribosome [J. Clin. Invest. 93: 1458-1464 (1994) and the like].
- Examples of the method for introducing a gene into a tissue include a receptor-mediated introduction method, a method of introducing into a cell with a carrier such as metal particles by a particle gun, a method of directly introducing a plasmid, and a method of introducing a positively charged polymer.
- Known methods for introducing genes into cells include, for example, lipofection, co-precipitation with phosphate, DEAE-dextran, and direct injection of DNA using a micro glass tube.
- a retrovirus vector As the virus vector, a retrovirus vector, an adenovirus vector, or an adeno-associated virus vector is known.
- DNA or RNA such as detoxified retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, box virus, poliovirus, simvis virus, SV40, HIV, or Sendai virus
- a gene encoding the polypeptides (a) to (d) can be introduced into a virus, and the gene can be introduced into the cell by infecting the cell with the virus.
- An anti-obesity agent, a therapeutic agent for diabetes, or a therapeutic agent for hyperlipidemia containing a polynucleotide encoding the polypeptides (a) to (d) is used to directly introduce a gene into the body.
- a liquid preparation that can be used for injection or infusion can be mentioned.
- the liquid preparation is prepared, for example, by dissolving in a buffer such as phosphate buffered saline (PBS) or a solvent such as physiological saline or sterilized water, and then, if necessary, by filtration with a filter. Sterilize and fill in sterile containers. If necessary, it can be in the form of a suspension, a cryoprotectant, or a centrifugal concentrated cryoprotectant.
- PBS phosphate buffered saline
- a solvent such as physiological saline or sterilized water
- the polynucleotide may be, for example, a half containing fat, fatty oil, lanolin, petrolatum, wax, liquid paraffin, plaster, plastic, darcols, higher alcohol, resin, glycerin, emulsifier, or suspending agent. It can be administered topically to the affected area as a solid ointment. Such an ointment is necessary Alternatively, it can be mixed with a hydrophilic polymer, molded into a sheet, and adhered to the affected area.
- an anti-obesity agent, a therapeutic agent for diabetes, or a therapeutic agent for hyperlipidemia containing the polynucleotide is performed by selecting an appropriate method and site depending on the type and symptom of the disease.
- Parenteral administration is preferred as the administration method. Specifically, for example, administration to the surface layer by subcutaneous, intradermal, intravascular, intramuscular, or ointment is possible. Administration to subcutaneous, intradermal, blood vessels, muscles, etc. can be performed by injection or catheter.
- the medicament of the present invention comprises a therapeutically effective amount or a pharmacologically effective amount sufficient to produce the intended effect in the treatment or prevention of obesity, diabetes, and / or hyperlipidemia.
- Confirmation of the effective amount in actual administration can be performed, for example, by measuring the degree of recovery of the target disease.
- the actual amount to be administered depends on various factors such as the condition, age, and weight of the individual to be treated, and is preferably determined such that the desired effect is exhibited without significant side effects. Is done. Those skilled in the art can easily determine such an effective amount, toxicity, and the like using known model animals.
- the amount of the active ingredient is usually preferably 0.1 ⁇ g to 200 mg per day in an adult. More preferably, it is 0 • 1 ⁇ g to 20 mg per day.
- polypeptides (a) to (d), which are the active ingredients in the present invention can be administered in various forms that can be administered as pharmaceuticals, such as health foods (preferably functional foods) or foods and drinks. It is also possible to give in the form.
- the food includes a beverage.
- health food means a food capable of exerting some effect on health, or a food which can be expected to have an effect
- functional food means the “healthy food”.
- bioregulatory functions eg, the functions of regulating the physiological systems such as the digestive system, circulatory system, endocrine system, immune system, and nervous system. And processed food.
- the health food of the present invention has a function of treating obesity, diabetes, and / or hyperlipidemia. Are preferred.
- the polypeptide-containing food composition of the polypeptides (a) to (d), which has an effect of improving obesity, diabetes, and / or hyperlipidemia” and “Obesity, diabetes, and / or Polypeptide-containing functional food materials of the polypeptides (a) to (d), which have an effect of improving hyperlipidemia, are also included in the present invention.
- the polypeptide-containing food composition of the polypeptides (a) to (d) can contain a carrier that can be used for food and other additives.
- the health food of the present invention can be prepared in the same manner as a general health food, except that it contains the polypeptides (a) to (d) as an active ingredient.
- the health food of the present invention can be prepared by adding an effective amount of the active ingredient to a substance that can be ingested as a food.
- the effective amount can be appropriately determined according to various factors such as the shape or type of the food, or the symptoms, age, and weight of the individual who takes the food.
- the amount of the active ingredient is usually preferably 1 ⁇ g to 2 g per day for an adult. More preferably, it is 1 ⁇ g to 200 mg per day.
- a targeting vector having an HSV_tk gene in order were prepared by the following method.
- mice AGF protein produced in the same manner as in Example 1 of WO03 / 083114
- the mouse-pub-genome sequence (including 90664-96900 of AC073775.2) was cut out. Further, the plasmid PBN2 was transformed into type III, and SEQ ID NO: 6 (
- PCR was performed using a primer set consisting of CTAGACTAGTTGCAAAGGCGTGCGGCGG artificial sequence IJ) and SEQ ID NO: 7 (about 2 Okbp 3 'short arm (mouse-pub-genome sequence 5. The long arm and the 3 'short arm were transferred to plasmid pPNT (Cell,
- the obtained targeting vector was cut with a restriction enzyme Notl, and ES cell line R1 (Proceedings of the National Academy of Sciences, Vol 90, 8424-8428,
- SEQ ID NO: 8 (including AGF exon 4 and exon 5)
- the obtained ES cell line was microinjected into blastocysts obtained from BDF 2 mice, the second generation of C57BL / 6 mouse and DBAZ2 mouse crosses, and the engineered embryos were implanted into the uterus.
- Procedure Chimera mice were born from mice that had received embryos and were pregnant.
- a heterozygous mouse hereinafter, referred to as an AGF heterozygous mouse
- AGF homozygous mice Homozygous mice (hereinafter referred to as AGF homozygous mice) were obtained by crossing AGF heterozygous mice.
- PCR was performed using the genomic DNA isolated from the tail of the offspring mouse as type I, and the genotype of the mouse was confirmed by the size of the DNA fragment generated by the PCR. That is, the tail was treated with proteinase II, and the DNA was extracted with phenol 'black mouth form. The extracted DNA was recovered by isopropanol precipitation and ethanol precipitation, and tris-EDTA buffer (Hereinafter referred to as TE solution). Based on the neomycin resistance gene sequence and the genomic sequence deleted by targeting, a primer consisting of the following nucleotide sequence was designed.
- Reverse primer SEQ ID NO: 12 (5'-ctacctacatccactcctac-3, mouse)
- PCR was performed on the obtained genomic DNA derived from pup mice. PCR was performed using DNA polymerase (ExTaq; Takara) at 95 ° C (5 minutes), followed by heat denaturation at 95 ° C (1 minute), 60 ° C (1 minute), and 72 ° C (1 minute). (1 minute) for 30 cycles, followed by an extension reaction at 72 ° C (7 minutes), and the size of the amplified fragment was examined. If a mutant allele is present, a 545 bp band is detected in the PCR for detecting the neomycin resistance gene.If a wild-type allele is present, a 322 bp band is detected in the PCR for detecting genomic DNA containing mouse AGF exon 1. You.
- the genotype of the mouse was determined.
- the band of the mutant allele was detected and the band of the wild type allele was not detected
- the AGF heterozygous KO mouse both the band of the mutant allele and the band of the wild type allele were detected.
- no band of the mutant allele was detected, and a band of the wild-type allele was detected.
- the genotype of the mouse was also examined by performing the Southern blot analysis of Reference Example 1 (2).
- a 6.5 kbp band of the mutant allele was detected, and in the AGF heterozygous K ⁇ mouse, both the 6.5 kbp of the mutant allele and the 4.6 kbp band of the wild-type arenole were detected.
- a 4.6 kbp band of the wild-type allele was detected.
- Tris-HCl pH 7.5
- 150 mmol / L NaCl 150 mmol / L NaCl, 0.05% (w / v) Tween20]
- an anti-mouse AGF antibody WO03 / 083114
- an anti-rabbit antibody WO03 / 083114
- CAG modified chicken beta-actin promoter with CMV-IE enhancer
- AGF transgenic mice (hereinafter referred to as CAG-AGF Tg mice) in which mouse AGF was forcibly expressed throughout the body under control were prepared.
- CAG-AGF Tg mice AGF transgenic mice in which mouse AGF was forcibly expressed throughout the body under control were prepared.
- mouse AGF full-length cDNA (WO03 / 083114) was transformed into type III,
- AGAAGCTTCACCATGGGGACCGCCAGGCTAC Artificial Rooster IJ DNA consisting of a base sequence as a primer set PCR (After reaction at 95 ° C for 10 minutes, 94 ° C for 15 seconds, 60 ° C for 30 seconds, and 72 ° C 45 cycles of a 2 minute reaction at C)
- the resulting PCR product was subcloned into a pZErO_2 cloning vector (Invitrogen).
- the obtained plasmid was digested with the restriction enzymes Hindlll and Sail, and inserted into Hindlll and Sail sites of the plasmid pBluescriptn SK (Stratagene) to prepare a plasmid pBS_mAGF having a full-length mouse AGF gene.
- the plasmid pU_San Hum
- Plasmid loxP_1_1 was introduced into plasmid pCAGlox71bsr treated with alkaline phosphatase.
- sequencing was performed using a T3 primer (SEQ ID NO: 16: AATTAACCCTCACTAAAGGG), and the nucleotide sequence of the region containing the inserted loxP sequence was examined.
- the nucleotide sequence read by the T3 primer was consistent with the nucleotide sequence represented by SEQ ID NO: 15, and it was confirmed that loxP and 1 ⁇ 71 were in the same direction.
- Plasmid 1 ⁇ _1 ⁇ 71 is digested with the restriction enzyme Spe I, and the resulting fragment containing the CAG promoter, 1 ⁇ 71 control system 1J, bsr, poly A signal control system lj, and loxP sequence is ligated into the plasmid pBS—mAGF— ⁇ geo Spel site. Then, the desired plasmid pBS-loxP-lox71-mAGF- ⁇ geo was prepared.
- FIG. 1 shows the structure of the obtained plasmid pBS-loxP-lox71-mAGF- ⁇ 60.
- This plasmid After digestion with the restriction enzyme Notl, a linear DNA fragment [CAG promoter (promoter), 1 ⁇ 71 system 1J, bsr, poly A signal sequence (pA), loxP system, mouse AGF cDNA system lj, and IRES- ⁇ — Geo—poly ⁇ sequence (including pA)].
- CAG promoter promoter
- 1 ⁇ 71 system 1J 1J
- bsr poly A signal sequence
- loxP system poly A signal sequence
- loxP system mouse AGF cDNA system lj
- IRES- ⁇ Geo—poly ⁇ sequence (including pA)
- ES cells in which AGF is constantly expressed under the control of the CAG promoter Using the ES cells of each clone in which the 1 ⁇ 71–1 ⁇ interval before the introduction of the CAG-Cre vector was not removed as a negative control, it was confirmed that AGF was expressed in the ES cells of the selected 15 clones. It was confirmed by Western blotting using the same anti-AGF antibody as in 3). That is, Western blotting was performed using a sample obtained by diluting ES cells with a lysis buffer and 2 ⁇ SDS sample buffer two-fold, and it was confirmed that AGF was expressed.
- Reverse primer system 1J number 18 (5 agccgggtcaacataacagc_3, mouse)
- PCR When PCR is performed using these primers, a 325 bp fragment is amplified from the transgene by PCR to detect AGF cDNA, and a 320 bp fragment is amplified by PCR to detect LacZ. Fragments of these sizes should not be amplified from mouse genomic DNA.
- PCR was performed on the resulting genomic DNA derived from mouse pups. PCR was performed using DNA polymerase (ExTaq; Takara) at 94 ° C (5 minutes), followed by heat denaturation at 94 ° C (1 minute), 62 ° C (1 minute 30 seconds), and 72 ° C. (1 minute 30 seconds), 28 cycles were performed, followed by extension at 72 ° C (7 minutes), and the size of the amplified fragment was examined.
- SEQ ID NO: 21 TCGTGTAGTAGCCGTGTGGTGT mouse
- SEQ ID NO: 22 SEQ ID NO: 22
- PCR was performed using Universal PCR Master Mix (Applied Biosystems).
- the PCR reaction is carried out by repeating an initial denaturation reaction at 95 ° C (10 minutes) and then repeating a cycle reaction consisting of 94 ° C (15 seconds) and 60 ° C (60 seconds) 45 times. Carried out.
- a standard curve for calculating the gene expression level was obtained by performing the same reaction using the above-mentioned cDNA or mouse genomic DNA as type III, and the gene expression level was calculated as a relative value between samples.
- the expression level of the AGF gene was increased in the tissue of the CAG-AGF Tg mouse as compared with the tissue of the WT mouse.
- the expression was significantly increased in skeletal muscle, BAT, and heart.
- the CAG—AGF Tg mouse weighed 19.5 g ⁇ 0.7 g (SD)
- the WT mouse weighed 23.5 g ⁇ 2.5 g (SD). It was found that the AGF Tg mouse weighed less.
- AGF homozygous mice, AGF heterozygous mice, and Rita-mate WT mice were normally bred on a standard diet. The weight of each mouse was measured every week until the age of 24 weeks. The result is shown in figure 2. As shown in FIG. 2, it was found that AGF homozygous mice began to gain weight at about 12 weeks of age as compared to WT mice, and thereafter continued to gain weight, resulting in marked obesity. AGF heterozygous K ⁇ mice had an intermediate phenotype between AGF homozygous KO mice and Ritamate WT mice.
- CAG-AGF Tg mice showed that weight gain was suppressed. To clarify the cause, organ weights were measured.
- the genital fat (WAT), brown fat (BAT), liver, heart, kidney, and spleen tissues of the CAG-AGF Tg mouse and Rita-Mate WT mouse were collected, and the tissue weight per body weight was measured.
- the study was conducted on 12-week-old mice bred on a standard diet and 12-week-old to 24-week-old mice bred on a high fat diet for 12 weeks. As a result, brown fat, liver, heart, kidney, and spleen were fed on a standard diet and a high fat diet. During growth, there was no change in tissue weight between CAG-AGF Tg mice and WT mice.
- the CAG-AGF Tg mouse had a lower tissue weight per body weight than the WT mouse in both the standard diet and the high fat diet. That is, it was shown that the weight increase was suppressed in the CAG-AGF Tg mice because the weight increase of white adipose tissue was suppressed. In other words, it was found that AGF had no effect on the weight of other organs and had an effect of suppressing an increase in adipose tissue weight due to obesity and the like.
- the results for white adipose tissue are shown in FIG. 3 (standard diet) and FIG. 4 (high fat diet load).
- the weight S was found to be increasing, and the organ weight was measured to clarify the cause.
- Reproductive fat (WAT), brown fat (BAT), liver, heart, kidney, and spleen of AGF homo KO mice, AGF hetero KO mice, and Ritamate WT mice of 20-week-old females fed a standard diet Each tissue was collected, and the tissue weight per body weight was measured. As a result, the tissue weight of brown fat, liver, heart, kidney, and spleen did not change in AGF homozygous KO mice, AGF heterozygous mice, and WT mice.
- the genital fat increased the tissue weight per mouse individual and per body weight of AGF homozygous mice compared to the WT mice.
- AGF heterozygous mice had an intermediate tissue weight between AGF homozygous mice and WT mice. That is, it was shown that the body weight increased in the AGF KO mice due to the increase in the weight of white adipose tissue such as genital adipose tissue.
- white adipose tissue such as genital adipose tissue.
- AGF K ⁇ mice have a phenotype opposite to that of CAG-AGF Tg mice, and suppresses the weight increase of adipose tissue without affecting other organ weights as the physiological activity of AGF. It became clear that it had an effect.
- the results for genital adipose tissue are shown in FIG. 5 (white adipose tissue weight) and FIG. 6 (white adipose tissue weight Z body weight).
- TG content in skeletal muscle (gastrocnemius muscle) and liver tissue of AGF KO mice was examined.
- TG in tissues was extracted from skeletal muscle and liver tissues of AGF KO mice and Rita-Mate WT mice by the method (1) described above.
- the concentration of the extracted TG was measured using a kit (Triglyceride Test Co .; Wako Pure Chemical Industries, Ltd.) to determine the TG content in the tissue.
- the results are shown in FIG. It was found that the TG content in the skeletal muscle and liver tissues was significantly increased in the AGF ⁇ mice compared to the WT mice.
- the AGF ⁇ ⁇ ⁇ mice were found to have the opposite phenotype as the CAG-AGF Tg mice, indicating that AGF has an activity of reducing TG content in skeletal muscle and liver as a physiological activity.
- a glucose tolerance test was performed on AGF homozygous K ⁇ mice and Rita-Mate WT mice, and blood glucose levels and blood insulin levels were examined. After fasting the mice for 16 hours, lg / kg of D-gunolose was administered by intraperitoneal injection (ip), and blood was collected from the ocular vein before administration and at 15, 30, 60, and 120 minutes after administration. The blood glucose level was measured using Daltest Ace (Sanwa Chemical Laboratory), and the blood insulin concentration was measured using the RIA2 antibody method (SRL). The results are shown in FIG. 13 (blood glucose level) and FIG. 14 (plasma insulin).
- the oxygen consumption of CAG-AGF Tg mice and Ritamate WT mice was measured. Using an oxygen consumption measuring device (OXYMAX; Columbus Instruments), the oxygen consumption of the mice was measured over a 24-hour period under fasting conditions. The measurement method followed the instruction manual attached to the oxygen consumption measuring device. The oxygen consumption of 14 CAG-AGF Tg mice and 14 littermate WT mice was measured, and 12 hours during the light period (7:00 to 19:00) and 12 hours during the ⁇ period (19:00 to 7 : 00), and 24-hour oxygen consumption were determined and compared between CAG-AGF Tg mice and WT mice. The results are shown in FIG. It was found that the CAG-AGF Tg mouse had a higher oxygen consumption (V ⁇ ) than the WT mouse at any time. As a result, AGF
- the primers shown in Table 1 were used as the primers used in the quantitative PCR of each gene.
- SYBR is used for / 3-actin.
- UCP1 was induced in BAT of CAG-AGF Tg mice, and the expression of UCP3, PPAR-a, and PPAR- ⁇ was induced in skeletal muscle of CAG-AGF Tg mice.
- AGF induced the expression of UCP1 in BAT and induced the expression of UCP3, PPAR-a, and PPAR-5 in skeletal muscle. This indicates that AGF enhances heat consumption and increases expression of UCP, and heat consumption and PPAR that enhances lipid metabolism.AGF increases oxygen consumption, suppresses weight gain, and suppresses adipose tissue weight increase. It is clear that this is one of the mechanisms of action.
- Human AGF and mouse AGF were expressed and purified according to the method described in WO03 / 083114 (Example 19). That is, an expression plasmid obtained by inserting a DNA fragment of about 1.4 kbp (human) or about 1.3 kbp (mouse) obtained by PCR into plasmid pcDNA-Signal-FLAG was introduced into HEK293 cells. The culture supernatant of the human AGF and mouse AGF expression cell lines was purified using the anti-FLAG-M2 monoclonal antibody agarose affinity gel (ANTI-FLAG).
- ANTI-FLAG anti-FLAG-M2 monoclonal antibody agarose affinity gel
- Affinity purification was performed using M2 Monoclonal Antibody Agarose Affinity Gel (Sigma) to obtain recombinant human and mouse AGF proteins.
- Plasmid pCR2.1-mNew (prepared in Example 1 of WO03 / 083114) containing the full-length mouse AGF cDNA was designated as type ⁇ , and a forward primer (
- PCR product was subcloned into pCR4Blunt_TOP ⁇ (manufactured by Invitrogen), cleaved with restriction enzymes Xbal and Notl, and C-terminal FLAG-added expression vector pCEP4dE2_FLAG cleaved with Xbal and Notl (Example 2 of WO02 / 42448).
- pCEPdE2_mAGF_FLAG was prepared by Invitrogen.
- PCR PyroBest DNA polymerase for PCR, PyroBest DNA polymerase
- a forward primer GAAGATCTACCATGGGGACCGCCAGGCTACGC; Torigami [J number 42]
- a reverse primer CCGCTCGAGTGATGGGACAGTCACAAGCGC; SEQ ID NO: 43.
- virus particles were prepared. Specifically, it was prepared by the following method.
- E. coli BJ5183 (manufactured by Stratagene) was transformed with plasmid pAdEasy-1 (He T.-C. et al., Proc. Natl. Acad. Sci. USA,
- Escherichia coli BJ5183 [hereinafter referred to as Escherichia coli BJ5183 (pAdEasy-1)] containing the plasmid pAdEasy-1.
- Escherichia coli BJ5183 pAdEasy-1
- the plasmid pAdTracK-CMV-mAGF or pAdTrack-CMV prepared above was cut with the restriction enzyme Pmel, and used to transform Escherichia coli BJ5183 (pAdEasy-1).
- Plasmids were prepared from the obtained transformant clones, and the cleavage pattern with the restriction enzyme Pacl was determined. Examined. 3 kb or 4.5 kb extra band
- the obtained virus particle concentration was determined in the same manner as in Example 15 of WO02 / 42448.
- mice AGF protein-expressing adenovirus and the pAdTrack_CMV control adenovirus prepared in Example 10 were ligated to the human embryonic kidney cell line 293 (ATCC number:
- CRL-1573 was infected at approximately 100 virus particles per cell. Specifically, 293 cells were seeded at 3 ⁇ 10 5 on a 6-well plate (Asahi Techno Glass) coated with type I collagen, and 2 mL of 10% FBS / penicillin 100 IU / mL, streptomycin 100 ig / mL / DMEM medium After culturing for 1, adenovirus 6 ⁇ 10 7 particles were added, cultivation was performed for 1 ⁇ , and replaced with 2 mL of penicillin 100 IU / mL and streptomycin 100 ⁇ g / mL / DMEM medium.
- the band was not detected when the supernatant infected with the control adenovirus was used as a sample, and only when the supernatant infected with the mouse AGF protein-expressing adenovirus was used as a sample, the expected mouse AGF molecular weight was increased. It was detected that the mouse AGF protein-expressing adenovirus prepared in Example 10 expressed the mouse AGF protein by the method of Example 11.
- PCR2.1-hNew a forward primer (reverse primer (AACTCGAGCAGCTTCAGGGGCCGAATGAGCATGGC; SEQ ID NO: 1))
- reverse primer AACTCGAGCAGCTTCAGGGGCCGAATGAGCATGGC; SEQ ID NO: 1
- PCR using PyroBest TM DNA polymerase (Takara Shuzo), 35 cycles of 98 ° C for 20 seconds, 64 ° C for 30 seconds and 74 ° C for 3 minutes in the presence of 5% formamide) gave.
- pCEP-hAGF The resulting PCR product was subcloned into pCR4Blunt-TOP ⁇ (manufactured by Invitrogen), cut with the restriction enzymes Hindlll and Xhol, and inserted into pCEP4 (Invitrogen) cut with Hindlll and Xhol to obtain pCEP-hAGF.
- pCR4Blunt-TOP ⁇ manufactured by Invitrogen
- An expression plasmid containing a DNA fragment of about 0.43 kbp and a full-length human AGF cDNA generated by cutting pCEP-hAGF with restriction enzymes Kpnl and Mlul (prepared in Example 19 of WO03 / 083114; hereinafter, pcDNA-SF-h (AGF) was cleaved with restriction enzymes Mlul and Xhol, and the resulting DNA fragment of about 0.98 kbp was transferred to the shuttle vector pAdTrack_CMV (Pro
- Virus particles were prepared using Natl. Acad. Sci. USA 95: 2509-2514, 1998). The obtained virus particle concentration was determined in the same manner as in Example 15 of WO02 / 42448.
- Purified full-length human AGF protein (Example 19 in WO03 / 083114) was immunized to Perian Heron to obtain an antibody. Immunizations were performed every two weeks using 500 / ig for the first immunization and 250 xg for the second to fourth immunizations. Two weeks after the final immunization, antiserum was obtained by whole blood collection. The antiserum was purified using a protein A column (manufactured by Amersham Bioscience) to obtain an IgG antibody (hereinafter, anti-SF-YP-030 IgG).
- Human fetal kidney cell line 293 was infected with the human AGF protein-expressing adenovirus and the pAdTrack_CMV control adenovirus prepared in Examples 10 and 12 in the same manner as in Example 11 to obtain a culture supernatant.
- Human AGF protein expression in the culture supernatant was detected using the same method as in Example 11, except that the anti-SF-YP-030 IgG prepared in Example 13 was used as the primary antibody.
- a band was detected in the AGF molecular weight, and it was clarified that the human AGF protein-expressing adenovirus prepared in Example 12 expressed human AGF protein by the method of Example 14.
- mice Female C57BLZ6 mice (CLEA) were fed a high fat diet (high fat diet 32; CLEA) from the age of 8 weeks. The mice on the high fat diet increased in body weight and became obese at the age of 38 weeks, which was about 54 g at the time of virus administration in this test.
- high fat diet 32 high fat diet 32
- mAGF-Adeno mouse AGF-expressing adenovirus
- Count-Adeno control adenovirus
- administration of the virus containing the AGF gene resulted in expression of the AGF protein in vivo, and it was found that this AGF protein caused weight loss.
- mice were fasted for 16 hours, then administered with 0.4 g / kg D-glucose by intraperitoneal injection (ip), and blood was collected from the ocular vein before administration and at 15, 30, 60, and 120 minutes after administration. . Blood glucose was measured using Daltest Ace (Sanwa Chemical Institute). Figure 16 shows the results.
- mice administered mAGF-Adeno had lower blood glucose levels and improved glucose tolerance than mice administered Cont-Adeno at all times after glucose administration. In other words, it became clear that glucose tolerance was improved by the action of AGF protein highly expressed in mAGF-Adeno-administered mice.
- a glucose tolerance test was performed on CAG-AGF Tg mice (Example 1) to examine the effect of AGF on improving glucose tolerance.
- Four-month-old female CAG-AGF Tg mice and ritamate WT mice were fasted for 16 hours, and then lg / kg of D-gunolose was administered by intraperitoneal injection (ip).
- Blood was collected from the ocular vein at 60, and 120 minutes. Blood glucose was measured using Gnoretest Ace (Sanwa Chemical Laboratory). The results are shown in FIG.
- CAG-AGF Tg mice showed lower blood glucose levels and improved glucose tolerance than Rita-mate WT mice at all times after glucose administration. That is, it was revealed that the glucose tolerance was improved by the action of the AGF protein highly expressed in the CAG-AGF Tg mouse.
- FIG. 21 shows the ratio of the blood glucose level after administration to the blood glucose level before insulin administration.
- CAG-AGF Tg mice had a greater decrease in blood glucose level than the Rita-mate WT mice at all times after insulin administration and had increased insulin sensitivity. That is, it was revealed that insulin sensitivity was enhanced by the action of AGF protein highly expressed in CAG-AGF Tg mice.
- Example 8 of WO03 / 083114 was produced.
- This mouse expresses AGF protein at a high level from epidermal cells. It is known that revascularization and tissue regeneration are caused. AGF highly expressed in epidermal cells exhibits anti-obesity and anti-diabetic effects as shown in Examples 3, 4, and 17 using mice with high expression of AGF throughout the body. It was confirmed.
- both the visceral fat and the subcutaneous fat showed that the weight of adipose tissue was significantly reduced in the K14-AGF Tg mouse compared to the Rita-mate WT mouse. That is, as in the case of CAG-AGF Tg mice, it was found that the expressed AGF had an antiobesity effect and an effect of reducing adipose tissue.
- FIG. 24 shows the ratio of the blood glucose level after administration to the blood glucose level before insulin administration.
- K14-AGF Tg mice had a greater decrease in blood glucose level than Rita-Mate WT mice at all times after insulin administration and had increased insulin sensitivity. That is, it was revealed that insulin sensitivity was enhanced by the action of AGF protein highly expressed in CAG-AGF Tg mice.
- Example 15 mouse AGF exhibited an effect of suppressing weight loss and an effect of improving glucose tolerance. Therefore, it was confirmed that human AGF had the same effect by performing the following test.
- Human AGF-expressing adenovirus (hAGF-Adeno) prepared in Example 12 and control Three adenoviruses (Cont-Adeno) were administered to each of the three mice in the same manner as in Example 15, but the body weight after 13 days decreased by an average of 4.6 g in hAGF-Adeno-administered mice, and in Cont-Adeno-administered mice. Average increased by 0, lg.
- Example 15 Furthermore, a glucose metabolism test was performed in the same manner as in Example 15 except that D-glucose injected intraperitoneally was 0.5 gZkg, and blood collection after administration was performed 30, 60, 90, and 120 minutes later. As shown in FIG. 25, it was revealed that the hAGF-Adeno-administered mice had lower blood glucose levels and improved glucose tolerance than the Cont-Adeno-administered mice at all times after glucose administration. In other words, it became clear that the action of hAGF protein highly expressed in hAGF-Adeno-administered mice caused weight loss and improved glucose tolerance.
- Example 21 Amount of AGF protein in blood of CAG-AGF Tg mouse >>
- CAG-AGF Tg mice In CAG-AGF Tg mice (Example 1), it was examined how much AGF protein was expressed in blood. Blood was collected from the fundus of 4-month-old female CAG-AGF Tg mice and Rita-Mate WT mice, and serum was obtained according to a standard method. The obtained serum was subjected to Western blotting in the same manner as in Reference Example 1 (3), and the AGF protein was detected. The results of Western blotting were captured with a scanner, and the concentration of AGF protein band was quantified using image analysis software (NIH image 1.62f). As a result, it was found that the AGF protein concentration in the serum was increased 2.4-fold in the CAG-AGF Tg mouse compared to the Rita-mate WT mouse.
- Example 22 Amount of AGF protein in blood of mouse to which mouse AGF-expressing adenovirus was administered >>
- Example 15 the amount of AGF protein in blood when a mouse AGF-expressing adenovirus was administered to mice was examined. Before and after administration of mouse AGF-expressing adenovirus and control adenovirus (day 0) and after administration: Blood was collected from the eyes of mice on days! 7 to 7, and serum was obtained according to a standard method. Western blotting was performed in the same manner as in Reference Example 1 (3), and AGF proteins were detected. As a result, it was found that the administration of the control adenovirus did not change the AGF protein concentration, but the administration of the mouse AGF-expressing adenovirus increased the AGF protein concentration over time after peaking on the fourth day.
- mice to which the mouse AGF-expressing adenovirus was administered were treated with AGF tandem on day 0 and day 4.
- the concentration of the protein band was quantified.
- administration of mouse AGF adenovirus increased the AGF protein concentration by 2.5 times.
- the K14-AGF Tg mice used in Examples 18 and 19 were examined for the extent to which AGF protein was expressed in blood.
- Blood was collected from the eye fundus of 8-month-old female K14-AGF Tg mice and Rita-mate WT mice, and serum was obtained according to a standard method.
- Western blotting was performed in the same manner as in Reference Example 1 (3), and the AGF protein was detected and quantified. As a result, it was found that the serum AGF protein concentration was increased 1.8-fold in CAG-AGF Tg mice as compared to Rita-mate WT mice.
- Peptide A was conjugated to the carrier protein Psicycloglobulin (SIGMA) to produce an antigen, and 100 / ig of the peptide was immunized every two weeks every eight weeks into Peas. One week after the final immunization, whole blood was collected to obtain serum. An affinity column was made with peptide A.
- the serum was affinity-purified using an affinity column to obtain an IgG antibody that binds to peptide A (hereinafter, anti-YP-030-A IgG).
- concentration of the antibody was determined by measuring the absorbance at 280 nm and setting the molecular extinction coefficient to 1.38.
- the bound fraction of Fab 'and HRP was collected by gel filtration using a Superdex 200 16Z60HR column, and the HRP-labeled anti-human An AGF antibody Fab 'fragment (HRP-anti-SF-YP-030 Fab') was obtained.
- the antibody concentration was determined by measuring the absorbance at 280 nm and setting the molecular extinction coefficient to 1.38.
- the anti-YP-030-A IgG prepared in Example 24 was added at 20 ⁇ g / mL to a microplate for ELISA (NUNC) at 100 ⁇ L / well and allowed to stand at 4 ° C. Aspirate the solution in the well, wash twice with PBS (phosphate buffered saline), add 300 ⁇ L / well of blocking solution (1% BSA, 0.05% NaN, PBS), and add Leave at room temperature at
- the purified standard human AGF protein is diluted to 100-0.39 ng / l with a diluent (1% BSA, PBS containing 0.05% Tween20).
- the solution was serially diluted 2-fold to mL, added at 100 ⁇ L / well, and reacted at 37 ° C for 1 hour.
- adjust the HRP-labeled antibody HRP-anti-SF-YP-030 Fab,
- Reaction was carried out for 0.5 hours at C. After washing 9 times with the washing solution, a TMBZ substrate solution (manufactured by IBL) was added at 100 ⁇ L / well, and reacted at room temperature for 30 minutes. Reaction stop solution (IN ⁇
- the absorbance at A450 nm was measured using Analysis using the program attached to Spectramax revealed that there was a concentration region where linearity could be obtained, and a calibration curve could be created. As described above, an ELISA system for detecting human AGF could be constructed.
- Example 27 Amount of human AGF protein in blood of mouse to which human AGF-expressing adenovirus was administered >>
- the amount of AGF protein in blood when human AGF-expressing adenovirus was administered to mice was examined.
- the human AGF-expressing adenovirus (hAGF-Adeno) and the control adenovirus (Cont-Adeno) prepared in Example 12 were administered in the same manner as in Example 20.
- hAGF-A Weight loss and improvement in glucose tolerance were similarly observed in deno-administered mice.
- blood was collected from the fundus oculi to obtain serum according to a conventional method.
- the amount of human AGF protein in the serum was measured using the ELISA system constructed in Example 26.
- the medicament of the present invention can be used for the treatment and / or prevention of obesity, diabetes, and / or hyperlipidemia.
- the description of "Artificial Sequence” is described in the numerical sequence heading ⁇ 223> in the following sequence listing.
- the base sequence represented by the IJ number 1, 6, 7, 9, 10, 13, 14, 16, 19, 20, and 40-44 is the primer sequence artificially synthesized.
- the base sequence represented by SEQ ID NO: 15 is a sequence containing ⁇ .
- the amino acid sequence IJ represented by the sequence of SEQ ID NO: 46 is the sequence of peptide A.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/547,567 US20080119404A1 (en) | 2004-04-05 | 2005-03-30 | Antiobesity Drug |
EP05727932A EP1736171A1 (en) | 2004-04-05 | 2005-03-30 | Antiobesity drug |
CA002561593A CA2561593A1 (en) | 2004-04-05 | 2005-03-30 | Antiobesity drug |
MXPA06011508A MXPA06011508A (es) | 2004-04-05 | 2005-03-30 | Farmaco antiobesidad. |
JP2006512047A JPWO2005097171A1 (ja) | 2004-04-05 | 2005-03-30 | 抗肥満薬 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-111501 | 2004-04-05 | ||
JP2004111501 | 2004-04-05 | ||
JP2004-351813 | 2004-12-03 | ||
JP2004351813 | 2004-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005097171A1 true WO2005097171A1 (ja) | 2005-10-20 |
Family
ID=35124841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006024 WO2005097171A1 (ja) | 2004-04-05 | 2005-03-30 | 抗肥満薬 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20080119404A1 (ja) |
EP (1) | EP1736171A1 (ja) |
JP (1) | JPWO2005097171A1 (ja) |
KR (1) | KR20070007894A (ja) |
CA (1) | CA2561593A1 (ja) |
MX (1) | MXPA06011508A (ja) |
WO (1) | WO2005097171A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1832660A1 (en) * | 2004-12-03 | 2007-09-12 | Astellas Pharma Inc. | Method of screening antiobesity drug |
JP2013121936A (ja) * | 2011-12-12 | 2013-06-20 | Jichi Medical Univ | 肥満・メタボリックシンドローム治療薬、及びその動物の治療方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090104210A1 (en) * | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
US9139629B2 (en) | 2010-06-05 | 2015-09-22 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002101039A1 (en) * | 2001-06-08 | 2002-12-19 | Sankyo Company, Limited | Method of testing drug for treating or preventing diseases such as hyperlipemia |
WO2003083114A1 (en) * | 2002-03-28 | 2003-10-09 | Yamanouchi Pharmaceutical Co., Ltd. | Antiopoietin-related growth factor |
WO2004108920A1 (ja) * | 2003-06-06 | 2004-12-16 | Astellas Pharma Inc. | 抗肥満薬のスクリーニング方法及び肥満モデル動物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972338A (en) * | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
US7164009B2 (en) * | 2000-09-15 | 2007-01-16 | Genentech, Inc. | Pro9821 polypeptides |
US20030125521A1 (en) * | 2001-06-20 | 2003-07-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20030224984A1 (en) * | 2001-06-20 | 2003-12-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
-
2005
- 2005-03-30 WO PCT/JP2005/006024 patent/WO2005097171A1/ja not_active Application Discontinuation
- 2005-03-30 EP EP05727932A patent/EP1736171A1/en not_active Withdrawn
- 2005-03-30 MX MXPA06011508A patent/MXPA06011508A/es unknown
- 2005-03-30 JP JP2006512047A patent/JPWO2005097171A1/ja active Pending
- 2005-03-30 CA CA002561593A patent/CA2561593A1/en not_active Abandoned
- 2005-03-30 US US11/547,567 patent/US20080119404A1/en not_active Abandoned
- 2005-03-30 KR KR1020067023086A patent/KR20070007894A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002101039A1 (en) * | 2001-06-08 | 2002-12-19 | Sankyo Company, Limited | Method of testing drug for treating or preventing diseases such as hyperlipemia |
WO2003083114A1 (en) * | 2002-03-28 | 2003-10-09 | Yamanouchi Pharmaceutical Co., Ltd. | Antiopoietin-related growth factor |
WO2004108920A1 (ja) * | 2003-06-06 | 2004-12-16 | Astellas Pharma Inc. | 抗肥満薬のスクリーニング方法及び肥満モデル動物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1832660A1 (en) * | 2004-12-03 | 2007-09-12 | Astellas Pharma Inc. | Method of screening antiobesity drug |
EP1832660A4 (en) * | 2004-12-03 | 2009-11-11 | Astellas Pharma Inc | METHOD FOR SCREENING A MEDICAMENT AGAINST OBESITY |
JP2013121936A (ja) * | 2011-12-12 | 2013-06-20 | Jichi Medical Univ | 肥満・メタボリックシンドローム治療薬、及びその動物の治療方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20070007894A (ko) | 2007-01-16 |
EP1736171A1 (en) | 2006-12-27 |
US20080119404A1 (en) | 2008-05-22 |
JPWO2005097171A1 (ja) | 2008-02-28 |
CA2561593A1 (en) | 2005-10-20 |
MXPA06011508A (es) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3726969B2 (ja) | Lsr受容体、その活性、そのクローニングならびにその肥満および関連する危険性または合併症の診断、予防および/または治療への応用 | |
US7951381B2 (en) | Method of stimulating epithelial cell proliferation by administration of gastrointestinal proliferative factor | |
AU739057B2 (en) | Novel polypeptide, novel DNA, and novel antibody | |
EP1595547A2 (en) | Use of the growth factor AMP for the treatment of gastrointestinal injuries and acute renal failure | |
WO2006004066A1 (ja) | S1-5を含有するタンパク質製剤 | |
MXPA02009393A (es) | Polipeptido y heterodimero de hormona glucoproteica similar a beta. | |
WO2005097171A1 (ja) | 抗肥満薬 | |
KR101004662B1 (ko) | 에너지 항상성에 관여하는 신규한 펩티드 | |
CN107412729A (zh) | 用于治疗肾病综合征和有关病症的方法 | |
CN1980686A (zh) | 抗肥胖药 | |
WO2004108920A1 (ja) | 抗肥満薬のスクリーニング方法及び肥満モデル動物 | |
JP2007209214A (ja) | インスリン分泌誘導剤、インスリン分泌誘導組成物及びその製造方法、遺伝子治療用ウイルスベクター | |
WO2000060932A1 (en) | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 | |
JP2006314242A (ja) | 哺乳動物由来の変異sdhc遺伝子を有する遺伝子組み換え動物 | |
JPWO2006059691A1 (ja) | 抗肥満薬のスクリーニング方法 | |
JP2003304778A (ja) | トランスジェニック非ヒト哺乳動物 | |
US20030176649A1 (en) | Vmglom gene and its mutations causing disorders with a vascular component | |
JPWO2006004066A1 (ja) | S1−5を含有するタンパク質製剤 | |
MXPA99006043A (en) | Novel peptide, novel dna, and novel antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2561593 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5693/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727932 Country of ref document: EP Ref document number: 2006512047 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/011508 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067023086 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580018356.7 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727932 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067023086 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11547567 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005727932 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11547567 Country of ref document: US |